These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7026809)

  • 1. The high price of federally regulated hemodialysis.
    Greenspan RE
    JAMA; 1981 Oct 23-30; 246(17):1909-11. PubMed ID: 7026809
    [No Abstract]   [Full Text] [Related]  

  • 2. Health policy report. Funding the End-Stage Renal-Disease Program.
    Iglehart JK
    N Engl J Med; 1982 Feb; 306(8):492-6. PubMed ID: 7035954
    [No Abstract]   [Full Text] [Related]  

  • 3. The first DRG: lessons from the end stage renal disease program for the prospective payment system.
    Maxwell JH; Sapolsky HM
    Inquiry; 1987; 24(1):57-67. PubMed ID: 2951335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The American health care system. The End Stage Renal Disease Program.
    Iglehart JK
    N Engl J Med; 1993 Feb; 328(5):366-71. PubMed ID: 8419833
    [No Abstract]   [Full Text] [Related]  

  • 5. Justice and cost-containment in end-stage renal disease.
    Johnstone BV
    J Contemp Health Law Policy; 1987; 3():65-84. PubMed ID: 10301637
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicare program; end-stage renal disease quality incentive program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2011 Jan; 76(3):627-46. PubMed ID: 21261127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reaping the whirlwind.
    Hospitals; 1981 Apr; 55(8):55-6. PubMed ID: 7009383
    [No Abstract]   [Full Text] [Related]  

  • 8. HCFA audits of dialysis providers too lax--GAO.
    Burns J
    Mod Healthc; 1993 Jun; 23(23):11. PubMed ID: 10126288
    [No Abstract]   [Full Text] [Related]  

  • 9. Shifting sand: dialysis funding and modality distribution in Ontario.
    Mendelssohn DC; Blake PG
    Nephrol News Issues; 1999 Mar; 13(3):31-2, 37. PubMed ID: 10382486
    [No Abstract]   [Full Text] [Related]  

  • 10. The success of medicare's end-stage renal-disease program: the case for profits and the private marketplace.
    Lowrie EG; Hampers CL
    N Engl J Med; 1981 Aug; 305(8):434-8. PubMed ID: 7019710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost methodologies in dialysis in relation to the Italian National Health Service].
    Baroni A; Airoldi ; Savoini GP; Ragazzoni E; Francescone P; Fabiano M; Agliata S; Cavagnino A
    Minerva Urol Nefrol; 1994 Mar; 46(1):17-22. PubMed ID: 8036546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding financial risk models: Implicationsfor nephrology practices and dialysis centers.
    Cellini GL
    Nephrol News Issues; 2016 Mar; 30(3):26-8, 30-3. PubMed ID: 27169216
    [No Abstract]   [Full Text] [Related]  

  • 13. High-technology medicine in China. The case of chronic renal failure and hemodialysis.
    Henderson GE; Murphy EA; Sockwell ST; Zhou JL; Shen JR; Li ZM
    N Engl J Med; 1988 Apr; 318(15):1000-4. PubMed ID: 3352684
    [No Abstract]   [Full Text] [Related]  

  • 14. ESRD system: symbol for change?
    Hospitals; 1982 May; 56(10):30, 32. PubMed ID: 7068132
    [No Abstract]   [Full Text] [Related]  

  • 15. Home dialysis costs less than outpatient dialysis.
    Blagg CR
    N Engl J Med; 1982 Feb; 306(7):431. PubMed ID: 7035952
    [No Abstract]   [Full Text] [Related]  

  • 16. Price of dialysis, unit staffing, and length of dialysis treatments.
    Held PJ; García JR; Pauly MV; Cahn MA
    Am J Kidney Dis; 1990 May; 15(5):441-50. PubMed ID: 2333866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of end-stage renal disease in Alabama.
    Melnick S
    Ala J Med Sci; 1983 Oct; 20(4):456-9. PubMed ID: 6359945
    [No Abstract]   [Full Text] [Related]  

  • 18. The politics of health cost containment: end-stage renal disease.
    Rettig RA
    Bull N Y Acad Med; 1980; 56(1):115-38. PubMed ID: 6986928
    [No Abstract]   [Full Text] [Related]  

  • 19. Provider-patient relations and treatment choice in the era of fiscal incentives: the case of the end-stage renal disease program.
    Bovbjerg RR; Held PJ; Diamond LH
    Milbank Q; 1987; 65(2):177-202. PubMed ID: 3614141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCFA: failing to acknowledge the unique characteristics of the ESRD patient.
    Kanter A; Nidetz M
    Nephrol News Issues; 1990 Feb; 4(2):23-6, 31. PubMed ID: 2320135
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.